Core Viewpoint - VERAXA Biotech AG has received shareholder approval for its merger with Veraxa Biotech Holding AG and the issuance of new shares, marking a significant step towards the completion of the business combination with Voyager Acquisition Corp [1][3]. Group 1: Merger Details - The merger will be executed as an absorption merger, with Veraxa Biotech Holding AG acquiring VERAXA and changing its name to Veraxa Biotech AG [2]. - An ordinary capital increase of up to CHF 223,400.00 was approved, allowing for the issuance of shares to Voyager's shareholders as part of the business combination [2]. Group 2: Management and Operations - VERAXA will continue to operate under its current management team, led by CEO Christoph Antz, ensuring continuity in leadership during the transition [2][3]. - The company aims to address the increasing demand for safer and more effective cancer therapies, focusing on antibody-drug conjugates and bispecific T cell engagers [3]. Group 3: Future Trading and Listing - Following the merger, the combined entity is expected to trade on NASDAQ under the symbol "VRXA," pending approval from Voyager's shareholders [3][4]. - The business combination agreement was finalized on April 22, 2025, with the expectation of becoming a publicly traded company upon closing [4].
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.